Bioengineered Lymphatic Vessels in Synthetic Matrices to Study Breast Cancer Cell Functions
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.202503325 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Rodi Odabasi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Lymphatic Vessels, Breast Neoplasms, Bioengineering. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.
Abstract (Originalsprache)
Lymphatic vessels play an important role in pathologies, such as cardiovascular diseases or metastasizing cancers. However, mechanisms involved in cancer metastasis through lymphatic vessels remain largely unknown. In this study, we engineer 3D lymphatic microvessels by co‐culturing human lymphatic endothelial cells (hLECs) with human bone marrow‐derived mesenchymal stromal cells (hBM‐MSCs) in synthetic and fully defined enzymatically crosslinked poly(ethylene glycol) (TG‐PEG) hydrogels. By tuning the stiffness of the TG‐PEG scaffolds, varying seeding densities of hLECs and hBM‐MSCs, and stimulation with lymphangiogenic factors, we identify suitable culture conditions for lymphatic network formation. Immunocytochemistry‐based evaluations reveal the formation of lymphatic structures consisting of hLECs that are ensheathed with basement membrane extracellular matrix components and hBM‐MSCs, which express perivascular‐specific markers. Finally, the addition of non‐invasive MCF‐7 and invasive MDA‐MB‐231 breast cancer cells to the forming lymphatic structures shows a clear negative influence of cancer cells on the length of lymphatic networks. Moreover, we observe a closer association of invasive than of non‐invasive cancer cells with the lymphatic networks, which can be inhibited by blocking of CCL21. Our findings present a promising approach to investigate the cancer microenvironment, as our model can serve as a tool to study physiological lymphangiogenesis and pathological phenomena in vitro.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
- Department Research, University Center for Dental Medicine Basel UZB, University of Basel, Basel, Switzerland.
- University Children's Hospital Zurich, Zurich, Switzerland.
- Macromolecular Engineering Laboratory, Department of Mechanical and Process Engineering, ETH Zurich, Zürich, Switzerland.
- Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
Förderung
- Swiss National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Odabasi, R., Krattiger, L. A., Kanari, M., Jacobs, M. A., Moser, L. O., Tibbitt, M. W., Halin, C., & Ehrbar, M. (2026). Bioengineered Lymphatic Vessels in Synthetic Matrices to Study Breast Cancer Cell Functions. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202503325
Vancouver
Odabasi R, Krattiger LA, Kanari M, Jacobs MA, Moser LO, Tibbitt MW, et al. Bioengineered Lymphatic Vessels in Synthetic Matrices to Study Breast Cancer Cell Functions. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202503325
BibTeX
@article{Odabasi2026,
author = {Odabasi, Rodi and Krattiger, Lisa A and Kanari, Magdalini and Jacobs, Mira A and Moser, Lukas O and Tibbitt, Mark W and Halin, Cornelia and Ehrbar, Martin},
title = {Bioengineered Lymphatic Vessels in Synthetic Matrices to Study Breast Cancer Cell Functions},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.202503325}
}
EUVIMED